Somatic Advantage 500 Advanced – Liquid Biopsy

The Comprehensive Liquid Biopsy Panel for Solid Cancers
Test Code
SLS162017
Book Now

What is Somatic Advantage 500 Advanced - Liquid Biopsy?

The Somatic Advantage 500 Advanced Liquid Biopsy (SA500 Advanced LB) detects somatic variants in 523 genes, including current and emerging biomarkers with comprehensive coverage of genes associated with standard guidelines as well as clinical trials in solid cancers.

Powered by a highly sensitive TruSight Oncology 500 ctDNA assay and high-throughput sequencing with NovaSeqTM X Plus, the SA500 Advanced LB Test identifies low-frequency somatic mutations from a minimally invasive peripheral blood sample for comprehensive tumor profiling.

Genes Covered/ No. of Genes/ Biomarkers Covered: 523 Genes, 55 Fusions, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI)

Who Is This Test For?

  • Patients with solid tumors who are unable to undergo tissue biopsy
  • Individuals requiring longitudinal monitoring of tumor genetics and treatment response
  • Patients with advanced disease, where rapid or repeated testing is needed

Key Features

  • Actionable Insights: Covers AMP Tier I/II/III variants in 523 genes
  • Broad Genomic Spectrum: Covers SNVs/InDels (523 genes), CNVs (59 genes), and gene fusions (23 genes)
  • Empowers Immuno-Oncology: Advanced algorithms enable precise analysis of TMB and MSI
  • Unparalleled Reliability: Utilizes UMI-based library preparation for high sensitivity and accuracy
  • Clear Insights: Simple, easy-to-read reports covering diagnostic, prognostic, and therapeutic biomarkers, along with relevant therapy recommendations and clinical trials
  • Strong Somatic Knowledge Base: 523 genes, 20,000 variants, 100+ FDA-approved drugs, 4,844 pathway interactions, manually curated molecular variant summaries and clinical therapy recommendations
  • Analytical Sensitivity: SNVs/InDels >99% at >0.5% LOD, CNVs >99% at LOD of >1.3 fold change for gene amplifications, Fusions >99% at >0.5% LOD
  • Coverage: Pre-UMI coverage 10,000x, Post-UMI coverage 1200x

Clinical Applications

  • Detects actionable mutations to guide targeted therapy selection
  • Identifies resistance mechanisms emerging during treatment
  • Supports real-time assessment of disease progression and therapy effectiveness
  • Provides an alternative when tissue samples are insufficient or inaccessible

All Solid Tumors, Comprehensive Profiling

Contact Us